Efficacy and safety of sivelestat in patients with acute lung injury in the intensive care unit
10.3760/cma.j.issn.1671-0282.2022.08.008
- VernacularTitle:西维来司他钠在重症监护室急性肺损伤患者中应用的有效性和安全性研究
- Author:
Yulei GU
1
;
Lili XIAO
;
Hui PEI
;
Dong XU
;
Yumin JIANG
;
Jiafeng XIE
;
Xiaofan ZHANG
;
Yujing MAO
;
Zhiqiang ZHU
Author Information
1. 郑州大学第一附属医院急诊重症监护室(EICU)，郑州 450000
- Keywords:
Acute lung injury;
Inflammatory cytokines;
Neutrophil elastase;
Sivelestat;
Oxygenation index;
Lung injury score
- From:
Chinese Journal of Emergency Medicine
2022;31(8):1061-1065
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of sivelestat, a neutrophil elastase (NE) inhibitor, in the treatment of acute lung injury (ALI) in the intensive care unit (ICU).Methods:A retrospective analysis was performed on 171 patients with ALI in the ICU of the First Affiliated Hospital of Zhengzhou University from June 2020 to June 2021, including 77 patients in the sivelestat group and 94 patients in the conventional treatment group. Acute physiology and chronic health evaluation (APACHE) Ⅱ score, Murray lung injury score, oxygenation index (PaO 2/FiO 2 ratio), inflammatory cytokines (IL-6, IL-10, TNF-α), ventilator-free days (VFD), the length of ICU stay, and the 28-day mortality were collected to assess the efficacy of sivelestat. At the same time, adverse reactions and laboratory test results within 30 days after the use of sivelestat were recorded to assess the safety. Results:Compared with conventional treatment, oxygenation index, Murray lung injury scores, IL-6, IL-10, and TNF-α were significantly improved after 7 days of sivelestat treatment. Compared with the conventional treatment group, the VFD was significantly longer ( P = 0.0119) and the length of ICU stay was significantly shorter ( P = 0.0269) in the sivelestat group. The mortality was 14.29% in the sivelestat group and 22.34% in the conventional treatment group and, with no statistically significant. In the meantime, sivelestat did not increase adverse reactions within 30 days after treatment. Conclusions:Sivelestat treatment is safe and more effective than conventional treatment for ALI patients in the ICU.
